- Home
- KGEI vs SGMT Comparison
KGEI vs SGMT Comparison
Compare KGEI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KGEI
- SGMT
- Stock Information
- Founded
- KGEI 2008
- SGMT 2006
- Country
- KGEI United States
- SGMT United States
- Employees
- KGEI N/A
- SGMT N/A
- Industry
- KGEI
- SGMT
- Sector
- KGEI
- SGMT
- Exchange
- KGEI Nasdaq
- SGMT Nasdaq
- Market Cap
- KGEI 254.9M
- SGMT 269.2M
- IPO Year
- KGEI N/A
- SGMT 2023
- Fundamental
- Price
- KGEI $6.14
- SGMT $9.23
- Analyst Decision
- KGEI Strong Buy
- SGMT Strong Buy
- Analyst Count
- KGEI 1
- SGMT 5
- Target Price
- KGEI $11.00
- SGMT $26.60
- AVG Volume (30 Days)
- KGEI 508.9K
- SGMT 1.1M
- Earning Date
- KGEI 08-11-2025
- SGMT 08-13-2025
- Dividend Yield
- KGEI N/A
- SGMT N/A
- EPS Growth
- KGEI 42.32
- SGMT N/A
- EPS
- KGEI 0.57
- SGMT N/A
- Revenue
- KGEI $60,739,000.00
- SGMT N/A
- Revenue This Year
- KGEI $32.19
- SGMT N/A
- Revenue Next Year
- KGEI $33.24
- SGMT N/A
- P/E Ratio
- KGEI $10.71
- SGMT N/A
- Revenue Growth
- KGEI 20.06
- SGMT N/A
- 52 Week Low
- KGEI $2.85
- SGMT $1.73
- 52 Week High
- KGEI $9.89
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- KGEI 43.83
- SGMT 66.16
- Support Level
- KGEI $5.55
- SGMT $8.49
- Resistance Level
- KGEI $6.08
- SGMT $9.95
- Average True Range (ATR)
- KGEI 0.51
- SGMT 0.68
- MACD
- KGEI -0.08
- SGMT -0.08
- Stochastic Oscillator
- KGEI 18.66
- SGMT 86.23
About KGEI Kolibri Global Energy Inc. Common stock
Kolibri Global Energy Inc is a North American energy company focused on finding and exploiting energy projects in oil, gas, and clean and sustainable energy. It is focused on the acquisition, exploration, and production of oil and gas reserves. The company owns and operates shale oil and gas properties in the United States. The company derives a majority of its revenue from the United States.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.